CBx Daily Digest

Feds Upgrade From Warnings To Lawsuits

What happens when you don’t listen to FDA warnings? They sue you, and they typically win. That’s the case with Thrive, a CA-based supplement maker who was sued by the FDA for not complying with warnings last year about cancer-related claims. Fast forward and the same company is making anti-viral claims associated with COVID-19. Yuck.

What happens when you don’t listen to FDA warnings? They sue you, and they typically win.

That’s the case with Thrive, a CA-based supplement maker who was sued by the FDA for not complying with warnings last year about cancer-related claims. Fast forward and the same company is making anti-viral claims associated with COVID-19. Yuck.

In response to a Federal Trade Commission complaint, a California-based marketer of a supplement consisting mainly of Vitamin C and herbal extracts has agreed to a preliminary order barring him from claiming that it is effective at treating, preventing, or reducing the risk of COVID-19.

Pending the resolution of a parallel administrative case, the proposed preliminary order also bars Marc Ching, doing business as Whole Leaf Organics, from claiming that three CBD-based products he sells are effective cancer treatments.

“There’s no proof that any product will prevent or treat COVID-19 or that any CBD product will treat cancer,” said Bureau of Consumer Protection Director Andrew Smith. “Let’s be clear: companies making these claims can look forward to an FTC lawsuit like this one.”

Of course, the agency doesn’t seem to sleep. According to Hemp Grower, Two more warnings were issued just last week, this time the FDA sent warning letters to two companies operating in the CBD space for violating the Federal Food, Drug and Cosmetic Act (FD&C Act), according to a news release from the agency.

To Top